Crinetics Pharmaceuticals CRNX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's business segments — net loss?
- Crinetics Pharmaceuticals (CRNX) reported business segments — net loss of -$127.85M in Q1 2026.
- How has Crinetics Pharmaceuticals's business segments — net loss changed year-over-year?
- Crinetics Pharmaceuticals's business segments — net loss decreased by 32.1% year-over-year, from -$96.77M to -$127.85M.
- What does business segments — net loss mean?
- Represents the bottom-line financial result where total expenses exceed total revenues for the reporting period. For a clinical-stage pharmaceutical company, this metric reflects the significant investment in research and development and commercial infrastructure relative to current product sales. It serves as a primary indicator of the company's cash burn and financial sustainability.